Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience

BACKGROUND: Patients with solid organ transplants (SOTs) have been excluded from programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical trials due to concern for allograft rejection. The use of immune checkpoint inhibitor therapy remains controversial in transplant pa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Gastrointest Oncol
Hlavní autoři: DeLeon, Thomas T., Salomao, Marcela A., Aqel, Bashar A., Sonbol, Mohamad B., Yokoda, Raquel T., Ali, Ahmad H., Moss, Adyr A., Mathur, Amit K., Chascsa, David M., Rakela, Jorge, Bryce, Alan H., Borad, Mitesh J.
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286929/
https://ncbi.nlm.nih.gov/pubmed/30603124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.07.05
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky